Sustained Long-term Safety and Tolerability of Foslevodopa/Foscarbidopa in Parkinson’s Disease: 96-week Primary Treatment Period Results from an Ongoing Open-label Extension Study (P11-5.006)

Evaluate the long-term safety, tolerability, and efficacy of foslevodopa/foscarbidopa (LDp/CDp) in people with advanced Parkinson’s disease (PD) treated through week 96 of an open-label extension study (OLES).